奥翔药业：甲磺酸伊马替尼片获药品注册证书

Core Viewpoint - The announcement highlights that Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Imatinib Mesylate Tablets, marking a significant milestone in cancer treatment [1]. Group 1: Company Developments - Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical, has been granted a drug registration certificate for Imatinib Mesylate Tablets [1]. - Imatinib Mesylate is recognized as the world's first targeted molecular therapy for cancer, specifically for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) [1]. Group 2: Product Details - Imatinib Mesylate Tablets are intended for patients in the accelerated phase or blast crisis of CML, as well as those with GIST who cannot undergo surgical resection or have metastatic disease [1]. - The active ingredient, Imatinib, functions as a tyrosine kinase inhibitor, effectively suppressing the Philadelphia chromosome gene and preventing abnormal white blood cell proliferation [1].